Navigation Links
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Date:9/6/2007

KNOXVILLE, TN--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) announced that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.

In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease. Dees continued, Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future.


'/>"/>
Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1

Related medicine news :

1. Risk of heart disease begins in teens
2. Cancer Begins With Epigenetic Changes: Study
3. Learning About Healthy Diet Choices Begins At Schools
4. China Begins Human Trials For HIV/AIDS Drug
5. Administration of Fish Drug for Asthma Patients Begins in Andhra
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Writing on the Wall - Lead Poisoning Begins at Home?Paints Could Be Toxic!
8. The Blessing of Good Mental Health Begins with Breast Milk, Says a Study
9. India sounds bird flu alert as migration season begins
10. Keys to Good Health in Old Age Begins in Midlife
11. Cancer Prevention Begins During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, a division ... credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare Staffing ... recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital Advisors provided ...
(Date:1/19/2017)... ... January 19, 2017 , ... Huntington Beach dental ... sleep apnea and TMJ disorders. These conditions are quite common particularly in midlife ... personalized care to reduce the risk of these consequences and improve overall wellbeing. ...
(Date:1/19/2017)... ... , ... Sam & Associates Insurance Agency, a full service firm providing asset ... Bay Area, is launching a charity drive to raise awareness of heart disease risk ... primary killer of adult men and women in America, and is responsible for over ...
(Date:1/19/2017)... ... January 19, 2017 , ... St. Catherine’s Village announced ... Siena Center is a skilled nursing facility on the grounds of the St. Catherine’s ... It recently was voted the best nursing home in Mississippi for the second year ...
(Date:1/19/2017)... ... January 18, 2017 , ... The CHP suggests that California ... rain storm by slowing down and increasing the space between themselves and other vehicles, ... based car accident attorney Raymond R. Hassanlou notes that, rain or shine, drivers should ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- The global  pacemaker market  is expected to reach USD 12.3 ... The heightening prevalence of cardiac conditions coupled with the availability of medical coverage ... technological enhancements in these devices are supporting the expansion of this vertical. ... ... Grand View Research Logo ...
(Date:1/19/2017)... Jan. 18, 2017   Synthetic Biologics, Inc. ... developing therapeutics designed to preserve the microbiome to ... confirmed plans to initiate a Phase 2b/3 adaptive ... of lovastatin lactone designed to reduce methane production ... the gut to treat the underlying cause of ...
(Date:1/18/2017)... Jan. 18, 2017  Aprima Medical Software, a ... practice management (PM) and revenue cycle management (RCM) ... of a former reseller Healthcare Data Solutions (HDS) ... agreement, Aprima will assume full support for HDS,s ... medical practices across 15 states. Financial terms were ...
Breaking Medicine Technology: